How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

582 results for

Antithyroid Antibody

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Graves' Disease Presenting with Periodic Paralysis to the Emergency Department (PubMed)

on a background of weight loss. Physical examination demonstrated symmetrical proximal muscle weakness with normal sensation and reflexes. Initial biochemical investigations revealed hypokalaemia, hypomagnesaemia, and hyperthyroidism. Intravenous electrolyte replacement was administered in the emergency department. The patient's symptoms resolved during inpatient admission. Subsequent TSH receptor antibody testing and radionuclide thyroid scan confirmed a diagnosis of Graves' disease. The patient (...) was discharged on antithyroid medication with no further episodes of weakness on follow-up. Therefore, thyrotoxic periodic paralysis can be the presenting feature of previously undiagnosed Graves' disease and should be considered in the differential diagnosis in patients presenting with weakness.

Full Text available with Trip Pro

2018 Case reports in endocrinology

102. Liver Function After Intravenous Methylprednisolone Administration

), anti-smooth muscle antibodies (ASMA), anti-mitochondrial antibodies (AMA) and anti-liver kidney-microsomal antibodies (anti-LKM) were also assessed. Thyroid evaluation included measurement of: thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), and serum antithyroid autoantibodies including anti-thyroid peroxidase (aTPO), thyroglobulin antibodies (aTG), thyroid-binding inhibitory immunoglobulin (TBII). According to EUGOGO recommendations: patients with moderate (...) in a magnetic resonance (MR) scan (presence of apical crowding and/or optic nerve stretching). Laboratory tests were performed before treatment in all patients from both evaluated groups. Serum markers of exposure to hepatitis B (HBV) and hepatitis C (HCV) were checked: hepatitis B surface antigen (HBs-Ag), hepatitis B surface antibody (HBs-Ab), hepatitis B core antibody (HBc-Ab), hepatitis C antibody (HCV-Ab). Serum autoantibodies associated with autoimmune hepatitis including anti-nuclear antibodies (ANA1

2018 Clinical Trials

103. A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

: Screening period (35 days) to complete eligibility assessments Open-label treatment period (6 months) Follow-up period (3 months) During the open-label treatment period, subjects will be randomized to receive romosozumab either via HCP administration with PFS or via self-administration withAI/Pen. During the follow-up period, subjects will be followed for an additional 3 months to ensure appropriate follow-up for anti-romosozumab antibody formation and adverse events. The primary analysis (...) events Incidence of subjects developing anti-romosozumab antibodies [ Time Frame: Month 6 ] Incidence of subjects developing anti-romosozumab antibodies Serum Chemistry [ Time Frame: Month 6 ] Change from baseline in serum chemistry Percent changes from baseline in BMD at femoral neck. [ Time Frame: Month 6 ] Percent changes from baseline in BMD at femoral neck. Incidence of treatment-emergent serious adverse events [ Time Frame: Month 6 ] Incidence of treatment-emergent serious adverse events

2018 Clinical Trials

104. Effects of Selenium Supplementation on Graves' Disease: A Systematic Review and Meta-Analysis (PubMed)

patients. Two reviewers searched PubMed, Web of Science, the Cochrane Central Register of Controlled Trials, and four Chinese databases for studies published up to October 31, 2017. RCTs comparing the effect of selenium supplementation on thyroid hyperfunction in GD patients on antithyroid medication to placebo were included. Serum free thyroxine (FT4), free triiodothyronine (FT3), thyrotrophic hormone receptor antibody (TRAb), and thyroid-stimulating hormone (TSH) levels were assessed. Ten trials

Full Text available with Trip Pro

2018 Evidence-based Complementary and Alternative Medicine : eCAM

105. Improvement of Chronic Idiopathic Urticaria With Levothyroxine: A Case Report and Review of Literature (PubMed)

. Laboratory investigations showed a high thyroid stimulating hormone (TSH) level and a low free thyroxine (T4) level. She had elevated levels of antithyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies (anti-TG). She was diagnosed as a case of Hashimoto's thyroiditis and started on levothyroxine therapy. She noticed that her uncontrolled recurrent urticaria started to get better and after a few months of therapy, she stopped taking her topical ointments and antihistamines. The reason

Full Text available with Trip Pro

2018 Cureus

106. Thyroid Function in Chronically Transfused Children with Beta Thalassemia Major: A Cross-Sectional Hospital Based Study (PubMed)

was ruled out by antithyroid peroxidase and antithyroglobulin antibody testing.A study population of 83 children consisted of 49 boys (59%) and 34 girls (41%). 4.8% of the children had evidence of subclinical hypothyroidism. Among them two belonged to the first decade and the other two to the second decade of life. Mean TSH, FT4, and ferritin values among children with thyroid dysfunction were 6.38 ± 0.83 mIU/ml, 1.08 ± 0.45 ng/dl, and 3983.0±1698.30 ng/ml, respectively. The severity of thyroid

Full Text available with Trip Pro

2018 International journal of pediatrics

107. Determination of Baseline Thyroid Status Values in French Adult Population

healthy volunteers group all healthy volunteers have a blood test performed in the same way. Other: Dosages of Thyroid parameters Dosages of the following parameters: TSH, FT4 FT3, TGAb (Tyroglobulin antibody) , TPO Ab (ThyroPeroxydase Antibody) Outcome Measures Go to Primary Outcome Measures : Determination of the usual values of TSH [ Time Frame: baseline ] Determination of the usual values of TSH after assays on DxI automaton of the Beckman Company according to the standardization 3rd international (...) Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Donors (18-70 years old) volunteers at EFS Exclusion Criteria: pregnancy, known antecedents of thyroid diseases (goiter, nodule, hypo or hyperthyroidism), current antithyroid treatment (neomercazole [Thyrozol(r)], levothyroxyn LT4 [levothyrox(r)], ...), cardiac treatment with amiodarone (cordarone(r)), injection of iodinated contrast medium less than 1 month old Contacts and Locations Go to No Contacts or Locations Provided More Information

2018 Clinical Trials

108. TPO-Ab plays a role in arterial remodeling in patients with intracranial stenosis. (PubMed)

TPO-Ab plays a role in arterial remodeling in patients with intracranial stenosis. Intracranial stenosis (ICS), the common cause of ischemic stroke worldwide, is associated with a high risk of recurrent stroke. We aimed to investigate the relationship between arterial remodeling and antithyroid peroxidase-antibody (TPO-Ab) level in ICS and the effect of TPO-Ab level on the migration of vascular smooth muscle cells (VSMCs).We analyzed data of mild-to-severe ICS patients with normal thyroid

2018 Atherosclerosis

109. Incidence of neonatal hyperthyroidism among newborns of Graves' disease patients treated with radioiodine therapy. (PubMed)

Incidence of neonatal hyperthyroidism among newborns of Graves' disease patients treated with radioiodine therapy. The serum thyrotropin receptor antibody (TRAb) titers of Graves' disease (GD) patients are known to increase after radioiodine (RAI) therapy, and they can remain high for years. The incidence of neonatal hyperthyroidism (NH) among newborns of mothers with GD who conceived after RAI therapy has not been previously reported. The aims of this study were to investigate the incidence (...) of NH among newborns of mothers who conceived within two years after RAI therapy, and to identify predictors of NH.GD patients (n = 145) who conceived within two years after RAI therapy were retrospectively reviewed, and information regarding their newborns was collected.Of the 145 pregnant women, 54 (37%) were treated with antithyroid drugs or potassium iodide for maternal hyperthyroidism during the first trimester. There were eight newborns with NH, resulting in an incidence of 5.5%. Seven

2018 Thyroid

110. A new highly thyrotropin receptor-selective small molecule antagonist with potential for the treatment of Graves' orbitopathy. (PubMed)

A new highly thyrotropin receptor-selective small molecule antagonist with potential for the treatment of Graves' orbitopathy. The thyrotropin receptor (TSHR) is the target for autoimmune thyroid stimulating antibodies (TSAb) triggering hyperthyroidism. Whereas elevated thyroid hormone synthesis by the thyroid in Graves' disease can be treated by antithyroid agents, for the pathogenic activation of TSHR in retro-orbital fibroblasts of the eye, leading to Graves' orbitopathy (GO), no causal TSHR

Full Text available with Trip Pro

2018 Thyroid

111. Hashimoto Encephalopathy (PubMed)

Hashimoto Encephalopathy Hashimoto encephalopathy (HE) is a steroid-responsive, acute or subacute encephalopathy, characterised by autoimmune thyroiditis associated with elevated antithyroid antibody titres. An 11-year-old girl was admitted to the Department of Paediatrics with generalised tonic-clonic seizures, left facial paralysis and right hemiparesis. Ceftriaxone and acyclovir were applied, and methyl prednisolone 2 mg kg-1 day-1 was administered orally. The hemiparesis improved on the 3rd (...) day of treatment, but the facial paralysis persisted into the 15th day. When she developed somnolence, she was transferred to the paediatric intensive care unit and provided with respiratory support after intubation. Antithyroid peroxidase (Anti-TPO) and Antithyroglobulin antibody (Anti-Tg) levels were measured at 112.3 IU mL-1 and 74.6 IU mL-1, respectively. HE was considered as the provisional diagnosis, for which intravenous methyl prednisolone 30 mg kg-1 for 5 days followed by prednisolone 1.5

Full Text available with Trip Pro

2018 Turkish journal of anaesthesiology and reanimation

112. Thyroid Cancer Treatment (PDQ®): Patient Version

of thyroid hormone and controls how fast follicular thyroid cells grow. The blood may also be checked for high levels of the hormone and antithyroid antibodies. : A procedure in which a blood sample is checked to measure the amounts of certain substances, such as , released into the blood by organs and tissues in the body. An unusual (higher or lower than normal) amount of a substance can be a sign of disease. Ultrasound exam : A procedure in which high-energy sound waves (ultrasound) are bounced off (...) are not cancer. Your doctor may find a lump ( ) in your thyroid during a routine medical exam. A thyroid nodule is an growth of thyroid in the thyroid. Nodules may be solid or -filled. When a thyroid nodule is found, an of the thyroid and a are often done to check for of . to check thyroid hormone levels and for antithyroid in the may also be done to check for other types of thyroid disease. Thyroid nodules usually don't cause or need treatment. Sometimes the thyroid nodules become large enough

2016 PDQ - NCI's Comprehensive Cancer Database

113. Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy

the same following the initial decrease in ATD therapy after 6 months. Methods: This prospective randomized clinical trial with observer blinded analysis will analyze 60 patients with moderate-to-severe GO who receive Tx versus ATD without surgery. Main outcome variables include: muscle index measurements via ultrasound and thyroid antibody levels. Additional outcome variables include: CAScore/NOSPECS score, superonasal index measurements via ultrasound and quality of life score. Condition or disease (...) Intervention/treatment Phase Graves Disease Graves Ophthalmopathy Graves' Ophthalmopathy Worsened Drug: Antithyroid Drug Procedure: Total thyroidectomy Phase 3 Detailed Description: Introduction: Graves disease (GD) is characterized by thyrotoxicosis and goiter, arising through circulating autoantibodies that bind to and stimulate the thyroid hormone receptor (TSHR). Graves' ophthalmopathy (GO) is characterized by inflammation, expansion of the extraocular muscles and an increase in retroorbital fat

2017 Clinical Trials

114. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. (PubMed)

are more prevalent in CSU than systemic (multiorgan or non organ-specific) AIDs. >2% of CSU patients have autoimmune polyglandular syndromes encompassing autoimmune thyroid disease (ATD) and vitiligo or pernicious anemia. Antithyroid and antinuclear antibodies are the most prevalent AID-associated autoantibodies in CSU. >15% of CSU patients have a positive family history for AIDs. The prevalence of urticarial rash in AID patients is >1% in most studies. This rash is more prevalent in eosinophilic

2017 Autoimmunity reviews


the treatment of overt hypothyroidism; the management and/or treatment of subclinical hypothyroidism, hypothyroxinemia or antithyroid antibody-positive women should be considered with caution. Important trials have found no clear benefit of treatment of subclinical hypothyroidism in terms of cognitive outcomes; however, other interventional studies appear to reduce some of the obstetric and perinatal complications. As a result, the dilemma between universal screening or selective screening of women at high

Full Text available with Trip Pro

2017 European Journal of Endocrinology

116. Single-Session High-Intensity Focused Ultrasound Treatment for Persistent or Relapsed Graves Disease: Preliminary Experience in a Prospective Study. (PubMed)

of the entire right and left thyroid lobes, with areas near the tracheal-esophageal groove and common carotid artery left unablated. Serum thyroid-stimulating hormone (TSH), free T4 (FT4), antithyroid autoantibodies, and TSH receptor (TSHR) antibody levels were evaluated afterward, and US color Doppler, US volumetry, and eye assessment were performed. The primary outcome was the 12-month relapse rate. Relapse referred to hyperthyroidism (FT4 > 23 pmol/L) afterward. Variables associated with relapse were (...) . No changes in gland volume, antithyroid autoantibody levels, and ophthalmic parameters were found at 12-month follow-up. Baseline TSHR was found to have decreased significantly at 6- and 12-month follow-up (P < .001 for both). TSHR antibody (odds ratio [OR] = 1.414; 95% CI: 1.018, 1.965; P = .039) and gland volume (OR = 0.557; 95% CI: 0.353, 0.880; P = .012) were associated with 12-month relapse, with higher antibody levels conferring a higher likelihood and smaller gland volumes conferring a lower

2017 Radiology


measurements of thyrotropin, thyroid hormones, and thyroid antibodies. In most cases, thyroid ultrasound and thyroid scintigraphy were performed. Demographic characteristics and the type and the duration of treatment were also reviewed.The incidence of II-Hypo was significantly higher after the increase in iodine supply than it was before (p < 0.001). After the increase in iodine supply, the incidence of II-Hyper was significantly lower than before the increase (p < 0.001). Furthermore, the portion (...) of patients with overt hyperthyroidism decreased, predominantly due to the increased proportion of patients with subclinical hyperthyroidism (p = 0.007 and p = 0.015, respectively). The duration of treatment with antithyroid drugs and perchlorate was significantly shorter after the increase in iodine supply than it was before (p = 0.001 and p = 0.002, respectively). A significantly positive correlation between the year of the occurrence of excessive iodine intake (EII)-induced thyroid disease

2017 Thyroid

118. Transient Hypothyroidism and Autoimmune Thyroiditis in Children with Chronic Hepatitis C Treated with Pegylated-Interferon-α-2b and Ribavirin. (PubMed)

and ribavirin (RBV).Sixty-one otherwise healthy children with CHC, 3-17 years of age, infected perinatally and treatment naïve, receiving therapy with pegylated IFN-α-2b and RBV and 183 age- and sex-matched controls were included in a multicenter, prospective, case-control study. Thyroid-stimulating hormone, free thyroxine, antithyroglobulin antibodies and antithyroid peroxidase antibodies were assessed before, during and 24 weeks after the end of treatment.From baseline to the end of treatment, subclinical (...) Transient Hypothyroidism and Autoimmune Thyroiditis in Children with Chronic Hepatitis C Treated with Pegylated-Interferon-α-2b and Ribavirin. Autoimmune thyroid disease and thyroid dysfunction are common in adults receiving interferon (IFN)-based treatment for chronic hepatitis C (CHC). Few data are available in children with CHC. This study is aimed to evaluate the appearance and timing of thyroid dysfunction and antithyroid autoimmunity in children with CHC treated with pegylated IFN-α-2b

2017 Pediatric Infectious Dsease Journal

119. Diplopia in a patient with Hashimoto's thyroiditis: A case report and literature review. (PubMed)

-associated blood tests were performed; surprisingly, the thyroid function test results were consistent with hypothyroidism and the antibody results such as antithyroglobulin and antithyroid peroxidase were markedly elevated, and the patient was diagnosed with Hashimoto's thyroiditis and treated with corticosteroids. Unfortunately, her diplopia was not relieved with medical management. Subsequently, a 9-mm left inferior rectus recession was performed.Clinicians should be aware of the atypical signs

Full Text available with Trip Pro

2017 Medicine

120. Serum 25-hydroxyvitamin D might be an independent prognostic factor for Graves disease recurrence. (PubMed)

Serum 25-hydroxyvitamin D might be an independent prognostic factor for Graves disease recurrence. Graves disease is the most common cause of thyrotoxicosis. Although medical intervention with antithyroid drugs (ATDs) is commonly the first choice of treatment in Korea, the remission rate associated with this approach is not satisfactory. During ATD therapy, low or undetectable serum levels of thyroid-stimulating hormone (TSH) receptor antibodies (TRAbs) have been reported to affect (...) -stimulating antibody [TSAb], as detected by bioassay, and TSH-binding inhibitory immunoglobulins [TBIIs]) were measured, and a thyroid function test was performed upon ATD discontinuation. Recurrence was evaluated every 3 months, and was defined as an occurrence of overt thyrotoxicosis during the follow-up period.A total of 95 patients (66.4%) experienced recurrence with a median latency period of 182 days (ranging 28-1219 days). The serum 25-hydroxyvitamin D levels at the time of ATD discontinuation were

Full Text available with Trip Pro

2017 Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>